Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19976648 | 0.91 | GBA1 (0.40) | GBA1OPRM1 | |
| SCHEMBL16521117 | 0.86 | GBA1 (0.44) | GBA1OPRM1ALDH1A1OPRD1 | |
| SCHEMBL22360704 | 0.79 | GBA1 (0.41) | GBA1OPRM1ALDH1A1 | |
| SCHEMBL25681706 | 0.76 | — | — | |
| SCHEMBL25681708 | 0.76 | — | — | |
| SCHEMBL22360701 | 0.76 | GBA1 (0.39) | GBA1OPRM1 | |
| SCHEMBL29341763 | 0.76 | GBA1 (0.39) | GBA1OPRM1 | |
| SCHEMBL23205043 | 0.74 | KCNJ1 (0.39) | GBA1ALDH1A1HSD11B1 | |
| SCHEMBL22360706 | 0.74 | GBA1 (0.38) | GBA1OPRM1 | |
| SCHEMBL25608578 | 0.74 | KCNJ1 (0.39) | GBA1ALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004123-B1 | RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-9920086-B2 | Ruthenium-based complexes, their preparation and use as catalysts | ARLANXEO DE GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| US-9828401-B2 | Ruthenium-based complex catalysts | ARLANXEO DEUTSCHLAND GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| EP-2744816-B1 | RUTHENIUM-BASED COMPLEX CATALYSTS | GOVERNING COUNCIL UNIV TORONTO (CA) | 2017-10-11 | — | — | EP | disclosed |
| US-20160090396-A1 | RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2016-03-31 | — | — | US | disclosed |
| US-20150057450-A1 | RUTHENIUM-BASED COMPLEX CATALYSTS | LANXESS DEUTSCHLAND GMBH (DE) | 2015-02-26 | — | — | US | disclosed |
| EP-2614887-A1 | Ruthenium-based complex catalysts | Lanxess Deutschland GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| WO-2013024119-A1 | RUTHENIUM-BASED COMPLEX CATALYSTS | THE GOVERNING COUNCIL OF UNIVERSITY OF TORONTO (CA) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057450-A1 | RUTHENIUM-BASED COMPLEX CATALYSTS | HIRIP3, SRP54, ORC3 | GBA1 4147/4885OPRM1 396/4885ALDH1A1 3544/4885 |
| US-20160090396-A1 | RUTHENIUM-BASED COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | TST, VARS1, NBAS | GBA1 3180/4885OPRM1 2193/4885ALDH1A1 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.